Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant

Aim: Fulvestrant is a drug used in the treatment of metastatic hormone receptor-positive breast cancer (mHRPBC). Although clinical trials have shown the efficacy of fulvestrant, real-life data are limited and data from clinical trials and real-life settings sometimes may be seen differently. Therefore, we retrospectively reviewed mHRPBC patients followed in our center and taking fulvestrant to evaluate the efficacy and clinical outcomes of the drug and also to identify factors affecting the efficacy and clinical outcomes of fulvestrant.Materials and methods: Patients who were followed up with the diagnosis of metastatic breast cancer between 2010 and 2022 and using fulvestrant were retrospectively analyzed.Results: The median progression-free survival (PFS) time was 9 [95% confidence interval (CI): 7.13-10.18] months and the median overall survival time was 28 (95% CI: 22.53-34.93) months. According to multivariate analyses, PFS was associated with age (p=0.041), body mass index (BMI) (p=0.043), brain metastasis (p=0.033), fulvestrant line (p=0.002), and use of pre-fulvestrant chemotherapy (p=0.032).Conclusion: Fulvestrant is an effective drug in mHRPBC. Fulvestrant is more effective in patients whose BMI index is under 30, without brain metastases, without prior chemotherapy, under 65 years of age, and used fulvestrant in the early treatment line. The efficacy of fulvestrant may vary according to age and BMI.

Automated summary

This study retrospectively analyzed mHRPBC patients receiving fulvestrant in our center to evaluate its efficacy and clinical outcomes, and identify factors affecting its efficacy and clinical outcomes. The results showed that fulvestrant is effective in mHRPBC, particularly in patients with BMI under 30, without brain metastasis, without prior chemotherapy, under 65 years of age, and using fulvestrant in the early treatment line. The efficacy of fulvestrant may vary according to age and BMI.